On 12 December 2019, SurGuide will host a breaskfast-session together with LSH010.
The programme is focussed on Rotterdam as a city for innovation in the life sciences. The following speakers will present in the plenary programme:
Dr. Senada Koljenović – Pathologist at Erasmus-university Medical Center
Dr. Koljenović is pathologist at the Erasmus-university Medical Center and pioneer in improving the standard of care for head and neck oncology patients. She is involved in multiple innovative programs on both national and European level such as the Dutch Cancer Society and Eurostars.
Dr. Koljenović has published multiple papers on the use of Raman spectroscopy for medical applications. Currently, she leads the development and implementation of a Raman spectroscopy based medical device for tumor margin assessment. Alongside this development, she has implemented a method to assess the resection margin intraoperatively which has resulted in a significant improvement of the standard of care in the Erasmus MC. www.erasmusmc.nl
Dr. Claus Schaffrath – CEO SurGuide B.V.
Claus Schaffrath is a physician and engineer with 20+ years of experience in Medical Devices and Image Guided Therapy, both in Hospital and Industry. Claus is an expert in Product Claim Management, a practice driven approach of value creation for Medical Devices.
SurGuide is a Rotterdam-based MedTech company that develops a platform technology for tumor resection control. SurGuide collaborates with experts in Raman spectroscopy and fiber-optics, RiverD International B.V. et art photonics GmbH and with medical specialists from the Erasmus-university Medical Center. Very recently, SurGuide has been nominated as finalist in the European Health Catapult 2019, a business plan competition for Europe’s best-in-class companies in BioTech, MedTech and Digital Health.
Dr. Cillian King – Investment manager Swanbridge Capital
Cillian joined the Swanbridge in 2018 following a career in strategic consultancy for early-stage ventures in the Life Sciences industry. As a consultant, Cillian gained extensive experience in the valuation of novel healthcare technologies, business development, project management, and non-dilutive funding.
In addition to working with early-stage ventures, Cillian was also involved in setting up several Dutch investment funds, including Swanbridge Capital in 2016. Cillian has a background in Molecular Biology (VU University and MIT) and a PhD in Molecular Neuroscience (VU University).
Swanbridge Capital, founded in 2016, is a Rotterdam-based venture capital firm that actively invests in young, high potential companies in the Life Sciences. At Swanbridge Capital, Cillian is responsible for sourcing and evaluating investment proposals, deal making, and the management of portfolio companies.
Follow the link below to subscribe for the meeting!